leisure time -WSS

leisure time

author：focus 2025-10-02 22:24:29 - browse：9589

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Solve the antibiotic resistance crisis with preventive drugs

hotspot

WSS

Lawmakers consider Medicare pay reforms for doctors

Researchers explore possible ties between long Covid, menopause

Medicare reduced heart disease by changing how it pays doctors

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Will Ozempic

2023 STAT Wunderkinds: get to know the winners

focus

leisure time

hotspot

How one medical school became remarkably diverse

CDC advisory group OKs chikungunya vaccine

Virginia high school admissions case could be legal follow

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

At least 13 dead in Texas as scorching temps continue

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

HHS leader on health, climate change and biopharma emissions

Jerome Adams on the need for new antivirals for Covid

STAT Summit: Biotech founders on deal

focus

First Opinion Podcast: Long Covid needs a new approach

Medicare Advantage isn’t working — for anyone

Virtual repurposing can help discover new uses for existing drugs

Pharmacists can make shortage drugs, but at what cost?

STAT Madness 2024: Meet the contenders

CDC advisory group OKs chikungunya vaccine

hotspot

hotspot

explore

leisure time